Using a higher cutoff for the percentage of HER2+ cells decreases interobserver variability in the interpretation of HER2 immunohistochemical analysis.

The effect of using a 30% cutoff for the proportion of HER2+ cells on the interobserver variability in the interpretation of HER2 immunohistochemical results was evaluated. Immunostained sections from 96 cases of breast carcinoma were reviewed by 10 pathologists and scored as positive (3+) when uniform strong membranous staining was identified in at least 10% of tumor cells; the actual percentage of cells with such staining was also estimated. The agreement rates and the kappa values using a 30% cutoff were compared with those using a 10% cutoff. These proved to be higher in 62% and 66% of measurements, respectively, with average interobserver rates and kappa values of 72% and 0.54 using the 30% cutoff and 70% and 0.49 using the 10% cutoff (P=.001 for all comparisons). Using a 30% cutoff for the percentage of HER2+ cells by immunohistochemical analysis modestly decreased interobserver variability in the interpretation of HER2 immunohistochemical results.

[1]  K. Shen,et al.  Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer , 2008 .

[2]  D. Chhieng,et al.  Does using a higher cutoff for the percentage of positive cells improve the specificity of HER-2 immunohistochemical analysis in breast carcinoma? , 2007, American journal of clinical pathology.

[3]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[4]  B. Ljung,et al.  HER2 testing in breast cancer: NCCN Task Force report and recommendations. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  Irene L Andrulis,et al.  HER2 and responsiveness of breast cancer to adjuvant chemotherapy. , 2006, The New England journal of medicine.

[6]  M. Hammond,et al.  Conference summary, Strategic Science symposium. Her-2/neu testing of breast cancer patients in clinical practice. , 2003, Archives of pathology & laboratory medicine.

[7]  Hung Chiang,et al.  Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest. , 2002, American journal of clinical pathology.

[8]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[9]  S. Ménard,et al.  Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.